Literature DB >> 7396138

Barbiturate therapy in the management of cerebral ischaemia.

M Belopavlovic, A Buchthal.   

Abstract

Two patients who underwent surgery for cerebral aneurysms are presented. In the first case 31 g thiopentone were given postoperatively over 20 h after the patient had already been comatose for many hours. Such high doses raise considerable problems in patient management. In the second case a loading dose of 50 mg/kg thiopentone was given prophylactically to a patient undergoing cerebral aneurysm surgery beginning at the induction of anaesthesia and before surface cooling was begun. Cerebral activity was monitored continuously with a cerebral function monitor (CFM). There was no significant cardiovascular depression, little delay in postoperative recovery and no permanent neurological sequelae. In cerebral aneurysm surgery, cerebral oedema following cerebral ischaemia, either associated with vasospasm or resulting from surgical occlusion of vessels, remains a major problem postoperatively and may be an indication for preventive treatment with barbiturates. The author contend that this technique merits further evaluation in cerebro-vascular surgery, especially in high risk cases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396138     DOI: 10.1111/j.1365-2044.1980.tb05095.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Interaction of thiopental with esomeprazole in critically ill patients.

Authors:  Amélie Marsot; Françoise Goirand; Nadine Milési; Monique Dumas; Audrey Boulamery; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2013-05-30       Impact factor: 2.953

2.  Phenobarbital and temperature profile during hypothermia for hypoxic-ischemic encephalopathy.

Authors:  Guilherme Sant'Anna; Abbot R Laptook; Seetha Shankaran; Rebecca Bara; Scott A McDonald; Rosemary D Higgins; Jon E Tyson; Richard A Ehrenkranz; Abhik Das; Ronald N Goldberg; Michele C Walsh
Journal:  J Child Neurol       Date:  2011-09-29       Impact factor: 1.987

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.